Skip to main content
SpringerLink
Log in

Comment on “Population Pharmacokinetics of Mycophenolic Acid: An Update”

  • Letter to the Editor
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

A Letter to the Editor to this article was published on 19 June 2018

The Original Article was published on 31 August 2017

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Kiang TKL, Ensom MHH. Population pharmacokinetics of mycophenolic acid: an update. Clin Pharmacokinet. 2018;57(5):547–58.

    Article  PubMed  CAS  Google Scholar 

  2. Woillard J-B, Bader-Meunier B, Salomon R, Ranchin B, Decramer S, Fischbach M, et al. Pharmacokinetics of mycophenolate mofetil in children with lupus and clinical findings in favour of therapeutic drug monitoring. Br J Clin Pharmacol. 2014;78:867–76.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  3. Prémaud A, Debord J, Rousseau A, Le Meur Y, Toupance O, Lebranchu Y, et al. A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil. Clin Pharmacokinet. 2005;44:837–47.

    Article  PubMed  Google Scholar 

  4. Prémaud A, Weber LT, Tönshoff B, Armstrong VW, Oellerich M, Urien S, et al. Population pharmacokinetics of mycophenolic acid in pediatric renal transplant patients using parametric and nonparametric approaches. Pharmacol Res. 2011;63:216–24.

    Article  PubMed  CAS  Google Scholar 

  5. Prémaud A, Le Meur Y, Debord J, Szelag J-C, Rousseau A, Hoizey G, et al. Maximum a posteriori bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods. Ther Drug Monit. 2005;27:354–61.

    Article  PubMed  Google Scholar 

  6. Kamar N, Marquet P, Gandia P, Muscari F, Lavayssière L, Esposito L, et al. Mycophenolic acid 12-hour area under the curve in de novo liver transplant patients given mycophenolate mofetil at fixed versus concentration-controlled doses. Ther Drug Monit. 2009;31:451–6.

    Article  PubMed  CAS  Google Scholar 

  7. Woillard J-B, Saint-Marcoux F, Monchaud C, Youdarène R, Pouche L, Marquet P. Mycophenolic mofetil optimized pharmacokinetic modelling, and exposure-effect associations in adult heart transplant recipients. Pharmacol Res. 2015;99:308–15.

    Article  PubMed  CAS  Google Scholar 

  8. Saint-Marcoux F, Royer B, Debord J, Larosa F, Legrand F, Deconinck E, et al. Pharmacokinetic modelling and development of Bayesian estimators for therapeutic drug monitoring of mycophenolate mofetil in reduced-intensity haematopoietic stem cell transplantation. Clin Pharmacokinet. 2009;48:667–75.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Saint-Marcoux F, Guigonis V, Decramer S, Gandia P, Ranchin B, Parant F, et al. Development of a Bayesian estimator for the therapeutic drug monitoring of mycophenolate mofetil in children with idiopathic nephrotic syndrome. Pharmacol Res. 2011;63:423–31.

    Article  PubMed  CAS  Google Scholar 

  10. Zahr N, Amoura Z, Debord J, Hulot J-S, Saint-Marcoux F, Marquet P, et al. Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategies. Clin Pharmacokinet. 2008;47:277–84.

    Article  PubMed  CAS  Google Scholar 

  11. Picard N, Prémaud A, Rousseau A, Le Meur Y, Marquet P. A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients. Br J Clin Pharmacol. 2006;62:477–84.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Musuamba FT, Rousseau A, Bosmans J-L, Senessael J-J, Cumps J, Marquet P, et al. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus. Clin Pharmacokinet. 2009;48:745–58.

    Article  PubMed  CAS  Google Scholar 

  13. de Winter BCM, Monchaud C, Prémaud A, Pison C, Kessler R, Reynaud-Gaubert M, et al. Bayesian estimation of mycophenolate mofetil in lung transplantation, using a population pharmacokinetic model developed in kidney and lung transplant recipients. Clin Pharmacokinet. 2012;51:29–39.

    Article  PubMed  Google Scholar 

  14. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007;46:13–58.

    Article  PubMed  CAS  Google Scholar 

  15. Shaw LM, Figurski M, Milone MC, Trofe J, Bloom RD. Therapeutic drug monitoring of mycophenolic acid. Clin J Am Soc Nephrol. 2007;2:1062–72.

    Article  PubMed  CAS  Google Scholar 

  16. Debord J, Risco E, Harel M et al. Application of a gamma model of absorption to oral cyclosporin. Clin Pharmacokinet. 2001;40:375–82.

    Article  PubMed  CAS  Google Scholar 

  17. Le Meur Y, Büchler M, Thierry A, Caillard S, Villemain F, Lavaud S, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant. 2007;7:2496–503.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Université Limoges, IPPRITT, 87000, Limoges, France

    Jean-Baptiste Woillard, Jean Debord & Pierre Marquet

  2. INSERM, IPPRITT, U1248, 87000, Limoges, France

    Jean-Baptiste Woillard, Jean Debord & Pierre Marquet

  3. Department of Pharmacology-Toxicology, CHU Limoges, 87000, Limoges, France

    Jean-Baptiste Woillard, Jean Debord & Pierre Marquet

Authors
  1. Jean-Baptiste Woillard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jean Debord
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pierre Marquet
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jean-Baptiste Woillard.

Ethics declarations

Conflict of interest

Jean-Baptiste Woillard, Jean Debord, and Pierre Marquet have no conflicts of interest to declare.

Funding

No sources of funding were received for the preparation of this letter.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Woillard, JB., Debord, J. & Marquet, P. Comment on “Population Pharmacokinetics of Mycophenolic Acid: An Update”. Clin Pharmacokinet 57, 1211–1213 (2018). https://doi.org/10.1007/s40262-018-0687-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40262-018-0687-9

Search

Navigation